Background: The traditional treatment of venous thromboembolism (VTE) with heparin
and warfarin has numerous limitations. New oral anticoagulants represent the promising alternative
with the potential to overcome the limitations of traditional treatment.
Objective: Apixaban is an oral factor Xa inhibitor with a rapid onset of action and predictable pharmacokinetics
that allows a fixed dose regimen. With this characteristic apixaban overcomes many limitations
and simplifies treatment of VTE eliminating the need for initial parenteral anticoagulant therapy
and laboratory monitoring.
Results: Fixed-dose regimen of oral apixaban alone is as effective as conventional treatment regimen and
is associated with a clinically relevant reduction of major bleeding. Extended anticoagulation with apixaban
with either a treatment dose (5 mg twice daily) or thromboprophylactic dose (2.5 mg twice daily) reduces
the risk of recurrent venous thromboembolism without increase in the rate of major bleeding.
Conclusion: Therefore, apixaban provides a simple, effective and safe alternative to conventional
acute or long-term treatment of VTE.